Journal of Parkinsons Disease

Papers
(The TQCC of Journal of Parkinsons Disease is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities219
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease102
The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease95
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects91
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 202086
The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease82
The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline81
Barriers and Motivators to Engage in Exercise for Persons with Parkinson’s Disease70
Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C’s that Will Shape the Future of Telemedicine66
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop63
Parkinson’s Disease and the COVID-19 Pandemic63
Young Onset Parkinson’s Disease: A Modern and Tailored Approach62
Infection and Risk of Parkinson’s Disease55
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations55
LRRK2 and the Endolysosomal System in Parkinson’s Disease48
Parkinsonism as a Third Wave of the COVID-19 Pandemic?48
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update47
Body-Worn Sensors for Remote Monitoring of Parkinson’s Disease Motor Symptoms: Vision, State of the Art, and Challenges Ahead46
Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson’s Disease43
Preventing Parkinson’s Disease: An Environmental Agenda43
Deep Phenotyping of Parkinson’s Disease42
Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment42
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update41
Digital Biomarkers of Mobility in Parkinson’s Disease During Daily Living40
Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk40
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis38
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease38
Management of Pain in Parkinson’s Disease37
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts35
Global Perspective on Telemedicine for Parkinson’s Disease35
Recommendations for Deep Brain Stimulation Device Management During a Pandemic35
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future34
Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes34
People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?33
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study32
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?32
Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson’s Disease During the COVID-19 Pandemic: New Expectations for the Future32
Oral Dysbiosis and Inflammation in Parkinson’s Disease32
Management of Orthostatic Hypotension in Parkinson’s Disease31
Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts31
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective31
Video-Based Analyses of Parkinson’s Disease Severity: A Brief Review31
Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson’s Disease30
Digital Therapeutics in Parkinson’s Disease: Practical Applications and Future Potential30
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture30
The Effects of Respiratory Training in Parkinson’s Disease: A Systematic Review30
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOV30
Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)29
Gait Kinematic Parameters in Parkinson’s Disease: A Systematic Review28
Freezing of Gait in People with Parkinson’s Disease: Nature, Occurrence, and Risk Factors27
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study27
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial27
Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction26
COVID-19 and Parkinson’s Disease: What Do We Know So Far?26
Does Gut Microbiota Influence the Course of Parkinson’s Disease? A 3-Year Prospective Exploratory Study in de novo Patients26
Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson’s Disease in the Harvard Biomarkers Study25
Neurophysiological Biomarkers of Parkinson’s Disease25
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations25
COVID-19 and Parkinson’s Disease: Are We Dealing with Short-term Impacts or Something Worse?25
The Universal Prescription for Parkinson’s Disease: Exercise24
Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results24
Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond24
Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience23
Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson’s Disease22
A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson’s Disease22
Proposal for a Biologic Staging System of Parkinson’s Disease22
Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson’s Disease Patients22
Cannabis in Parkinson’s Disease: The Patients’ View22
Animal Models of Parkinson’s Disease: Are They Useful or Not?21
Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson’s Disease21
ParkinSong: Outcomes of a 12-Month Controlled Trial of Therapeutic Singing Groups in Parkinson’s Disease21
Genetics of Progressive Supranuclear Palsy: A Review21
The Human Hippocampus in Parkinson’s Disease: An Integrative Stereological and Proteomic Study21
The Impact of Deep Brain Stimulation on Sleep in Parkinson’s Disease: An update21
Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson’s Disease21
Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson’s Disease: A Randomized Controlled Trial21
Quantitative Gait Analysis Using a Pose-Estimation Algorithm with a Single 2D-Video of Parkinson’s Disease Patients21
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions21
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease20
COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel?20
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion20
Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study20
Individually Tailored Internet-Based Cognitive-Behavioral Therapy for Daily Functioning in Patients with Parkinson’s Disease: A Randomized Controlled Trial20
Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson’s Disease20
Slow Wave Sleep and EEG Delta Spectral Power are Associated with Cognitive Function in Parkinson’s Disease20
Protein Quality Control Pathways at the Crossroad of Synucleinopathies20
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease20
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?19
Effects of Helicobacter pylori on Levodopa Pharmacokinetics19
Sexual Dysfunction in Early-Onset Parkinson’s Disease: A Cross-Sectional, Multicenter Study19
Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota19
A Practical Approach to Early-Onset Parkinsonism19
Age at Onset of Parkinson’s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations19
Personalized Care Management for Persons with Parkinson’s Disease19
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials18
Changes to Ventilation, Vocalization, and Thermal Nociception in the Pink1–/– Rat Model of Parkinson’s Disease18
Oral Health Disorders in Parkinson’s Disease: More than Meets the Eye18
A Dual Centre Study of Pain in Parkinson’s Disease and Its Relationship with Other Non-Motor Symptoms18
Diabetes Mellitus and Parkinson’s Disease: A Systematic Review and Meta-Analyses18
Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson’s Disease?17
Clinical Relevance of Standardized Mobile Gait Tests. Reliability Analysis Between Gait Recordings at Hospital and Home in Parkinson’s Disease: A Pilot Study17
Microglia in Parkinson’s Disease17
Multimorbidity and Frailty: Tackling Complexity in Parkinson’s Disease17
Prevalence of Prodromal Symptoms of Parkinson’s Disease in the Late Middle-Aged Population17
T Lymphocytes in Parkinson’s Disease17
What People with Parkinson’s Disease Want17
Comprehensive Analysis of Brain Volume in REM Sleep Behavior Disorder with Mild Cognitive Impairment16
Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers16
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease16
Parkinson’s Disease in African Americans: A Review of the Current Literature16
A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model16
Crosstalk Between Alpha-Synuclein and Other Human and Non-Human Amyloidogenic Proteins: Consequences for Amyloid Formation in Parkinson’s Disease16
Unhealthy Behaviours and Risk of Parkinson’s Disease: A Mendelian Randomisation Study16
Effectiveness of Long-Term Physiotherapy in Parkinson’s Disease: A Systematic Review and Meta-Analysis16
Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson’s Disease16
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson’s Disease: A Feasibility Study16
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies15
Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer15
The Gut Mycobiome in Parkinson’s Disease15
Management of Sleep Disturbances in Parkinson’s Disease15
Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson’s Disease Living in the United Kingdom15
Non-Genetic Risk Factors for Parkinson’s Disease: An Overview of 46 Systematic Reviews15
Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis15
A Long Way to Go: Patient Perspectives on Digital Health for Parkinson’s Disease15
Quantitative Electroencephalography Characteristics for Parkinson’s Disease: A Systematic Review15
Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson’s Disease15
Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients14
A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care14
The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson’s Disease14
Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson’s Disease14
CLOVER-DBS: Algorithm-Guided Deep Brain Stimulation-Programming Based on External Sensor Feedback Evaluated in a Prospective, Randomized, Crossover, Double-Blind, Two-Center Study14
Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson’s Disease14
Repetitive Motor Control Deficits Most Consistent Predictors of Conversion to Freezing of Gait in Parkinson’s Disease: A Prospective Cohort Study14
Minority Enrollment in Parkinson’s Disease Clinical Trials: Meta-Analysis and Systematic Review of Studies Evaluating Treatment of Neuropsychiatric Symptoms14
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?14
Role of NLRP3 Inflammasome in Parkinson’s Disease and Therapeutic Considerations14
Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment14
Challenges and Perspectives in the Management of Late-Stage Parkinson’s Disease14
Predictors of Conversion to α-Synucleinopathy Diseases in Idiopathic Rapid Eye Movement Sleep Behavior Disorder14
Barriers to Accessing Healthcare Services for People with Parkinson’s Disease: A Scoping Review13
Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson’s Disease13
Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review13
SNCA Hypomethylation in Rapid Eye Movement Sleep Behavior Disorder Is a Potential Biomarker for Parkinson’s Disease13
An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function13
Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson’s Disease13
Clinical Progression of Parkinson’s Disease: Insights from the NINDS Common Data Elements13
“How Long Can I Carry On?” The Need for Palliative Care in Parkinson’s Disease: A Qualitative Study from the Perspective of Bereaved Family Caregivers13
Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person13
Short Pulse and Conventional Deep Brain Stimulation Equally Improve the Parkinsonian Gait Disorder13
Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls13
Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson’s Disease by Autophagy Activation12
Lipidomics Prediction of Parkinson’s Disease Severity: A Machine-Learning Analysis12
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes12
T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of α-Synuclein Fibrils12
Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson’s Disease: A 7 Tesla Imaging Study12
Perturbation of in vivo Neural Activity Following α-Synuclein Seeding in the Olfactory Bulb12
Endoplasmic Reticulum Stress Regulators: New Drug Targets for Parkinson’s Disease12
Dual-Task Costs of Quantitative Gait Parameters While Walking and Turning in People with Parkinson’s Disease: Beyond Gait Speed12
How Time Rules: Diurnal Motor Patterns in de novo Parkinson’s Disease12
Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective12
Does Ethnicity Influence Recruitment into Clinical Trials of Parkinson’s Disease?12
Induction of Parkinsonian-Like Changes via Targeted Downregulation of Astrocytic Glutamate Transporter GLT-1 in the Striatum11
Irritable Bowel Syndrome and Risk of Parkinson’s Disease in Finland: A Nationwide Registry-Based Cohort Study11
Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review11
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease11
A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson’s Disease: A Qualitative Study11
NEAT1 on the Field of Parkinson’s Disease: Offense, Defense, or a Player on the Bench?11
Digital Health Technology to Measure Drug Efficacy in Clinical Trials for Parkinson’s Disease: A Regulatory Perspective11
Reaching and Grasping Movements in Parkinson’s Disease: A Review11
Dopamine Cell Therapy: From Cell Replacement to Circuitry Repair11
The Associations Between Physical Activity, Sleep, and Mood with Pain in People with Parkinson’s Disease: An Observational Cross-Sectional Study11
Cognitive Function and Quality of Life in Parkinson’s Disease: A Cross-Sectional Study11
Exercise Promotes Neurite Extensions from Grafted Dopaminergic Neurons in the Direction of the Dorsolateral Striatum in Parkinson’s Disease Model Rats11
Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson’s Disease: Data from the PPMI Study11
Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity11
New Insights and Implications of Natural Killer Cells in Parkinson’s Disease11
Smartphones for Remote Symptom Monitoring of Parkinson’s Disease11
Recruitment for Remote Decentralized Studies in Parkinson’s Disease11
Diet Quality and Risk of Parkinson’s Disease: A Prospective Study and Meta-Analysis11
Melanopsin Cell Dysfunction is Involved in Sleep Disruption in Parkinson’s Disease11
The Use of Digital Technology and Media in German Parkinson’s Disease Patients11
Pre-Movement Cortico-Muscular Dynamics Underlying Improved Parkinson Gait Initiation after Instructed Arm Swing11
Respiratory Disorders in Parkinson’s Disease10
Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment10
Perceptions of Compensation Strategies for Gait Impairments in Parkinson’s Disease: A Survey Among 320 Healthcare Professionals10
Constipation Predicts Cognitive Decline in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group10
Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson’s Disease in Women than in Men10
Worsened Parkinson’s Disease Progression: Impact of the COVID-19 Pandemic10
Locus Coeruleus Pathology Indicates a Continuum of Lewy Body Dementia10
Happiness: A Novel Outcome in Parkinson Studies?10
Tremor in Parkinson’s Disease May Arise from Interactions of Central Rhythms with Spinal Reflex Loop Oscillations10
Inflammasome Activation in Parkinson’s Disease10
Life with Parkinson’s Disease During the COVID-19 Pandemic: The Pressure Is “OFF”10
Predictors of Pharyngeal Dysphagia in Patients with Parkinson’s Disease10
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?10
Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry10
High IQ in Early Adulthood Is Associated with Parkinson’s Disease10
Subthalamic Stimulation for Camptocormia in Parkinson’s Disease: Association of Volume of Tissue Activated and Structural Connectivity with Clinical Effectiveness10
Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson’s Disease in the ICICLE-PD Cohort10
Management of Visual Dysfunction in Patients with Parkinson’s Disease10
0.029874086380005